Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
In plain words A Phase 1 study of gotu kola in people 60 to 85, run by Oregon Health and Science University. It plans to enroll about 48 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 85. Conditions: Mild Cognitive Impairment; Alzheimer's Disease.
- Age 60-85, male and female
- Sufficient English language skills to complete all tests
- Sufficient vision and hearing to complete all tests
- No known allergies to Centella asiatica
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Centella asiatica product; Placebo
Registered summary
This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.
Where, as registered
1 US site in 1 state.